All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

efavirenz 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals	989	154598-52-4

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: efavirenz stocrin (-)-efavirenz sustiva

Efavirenz is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1. Efavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1 reverse transcriptase. HIV-2 RT and human cellular DNA polymerases alpha, beta, gamma, and delta are not inhibited by efavirenz. Molecular weight: 315.68 Formula: C14H9ClF3NO2 CLOGP: 3.92 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 38.33 ALOGS: -4.57 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	27.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	42.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma)	0.01 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
May 28, 1999	EMA	Bristol-Myers Squibb Pharma EEIG
Sept. 17, 1998	FDA	BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abortion spontaneous	724.60	25.53	271	9358	46924	63432469
Viral mutation identified	622.86	25.53	122	9507	1688	63477705
Maternal exposure during pregnancy	564.34	25.53	372	9257	219690	63259703
Virologic failure	523.22	25.53	106	9523	1756	63477637
Abortion induced	443.50	25.53	129	9500	10113	63469280
Pregnancy	421.06	25.53	171	9458	36665	63442728
Immune reconstitution inflammatory syndrome	403.11	25.53	107	9522	5977	63473416
Exposure during pregnancy	388.06	25.53	259	9370	155288	63324105
Stillbirth	378.15	25.53	104	9525	6646	63472747
Drug resistance	334.18	25.53	127	9502	22806	63456587
Pathogen resistance	296.52	25.53	85	9544	6313	63473080
Normal newborn	253.34	25.53	80	9549	8261	63471132
Foetal exposure during pregnancy	248.29	25.53	113	9516	31849	63447544
Lipodystrophy acquired	184.11	25.53	43	9586	1409	63477984
Blood HIV RNA increased	171.97	25.53	36	9593	703	63478690
Caesarean section	160.49	25.53	69	9560	16963	63462430
Live birth	130.71	25.53	68	9561	25562	63453831
Viral load increased	109.46	25.53	28	9601	1346	63478047
Premature delivery	104.13	25.53	62	9567	30219	63449174
Cerebellar ataxia	95.03	25.53	23	9606	879	63478514
Treatment noncompliance	92.23	25.53	62	9567	37263	63442130
Birth mark	91.77	25.53	17	9612	170	63479223
Lactic acidosis	86.08	25.53	60	9569	38227	63441166
Congenital umbilical hernia	83.04	25.53	17	9612	296	63479097
Pregnancy with implant contraceptive	82.53	25.53	26	9603	2657	63476736
Fanconi syndrome acquired	81.98	25.53	21	9608	1015	63478378
Pulmonary tuberculosis	80.35	25.53	29	9600	4488	63474905
Pregnancy on contraceptive	79.06	25.53	21	9608	1171	63478222
Cleft lip and palate	71.06	25.53	17	9612	618	63478775
Paroxysmal extreme pain disorder	68.11	25.53	12	9617	88	63479305
Degenerative bone disease	67.56	25.53	13	9616	162	63479231
Chronic respiratory disease	66.49	25.53	13	9616	177	63479216
Confusional arousal	65.19	25.53	13	9616	197	63479196
Post procedural hypothyroidism	61.51	25.53	13	9616	266	63479127
Ectopic pregnancy	59.19	25.53	20	9609	2547	63476846
Portal hypertension	55.00	25.53	21	9608	3798	63475595
Autoimmune hepatitis	53.40	25.53	26	9603	8484	63470909
Hepatic cytolysis	51.52	25.53	31	9598	15376	63464017
Drug interaction	50.64	25.53	109	9520	229022	63250371
Hepatitis fulminant	49.72	25.53	19	9610	3445	63475948
CD4 lymphocytes decreased	48.81	25.53	15	9614	1412	63477981
Nephropathy toxic	47.86	25.53	25	9604	9454	63469939
Fatigue	47.83	25.53	39	9590	887989	62591404
Immune reconstitution inflammatory syndrome associated tuberculosis	47.12	25.53	11	9618	359	63479034
Malaria	47.07	25.53	10	9619	210	63479183
Tuberculosis	46.64	25.53	26	9603	11185	63468208
Premature baby	45.43	25.53	32	9597	20703	63458690
Mouth injury	44.81	25.53	13	9616	1004	63478389
Foetal death	44.42	25.53	25	9604	10955	63468438
Cholestatic liver injury	43.60	25.53	16	9613	2594	63476799
Hydrops foetalis	41.70	25.53	11	9618	597	63478796
Dyslipidaemia	41.67	25.53	21	9608	7372	63472021
Ultrasound antenatal screen	41.17	25.53	9	9620	217	63479176
Hepatomegaly	39.95	25.53	24	9605	11865	63467528
Premature rupture of membranes	39.80	25.53	18	9611	4975	63474418
Neurotoxicity	39.04	25.53	27	9602	16963	63462430
Drug ineffective	38.77	25.53	62	9567	1044703	62434690
Spinocerebellar disorder	38.45	25.53	6	9623	18	63479375
Abdominal discomfort	37.42	25.53	3	9626	320882	63158511
Abnormal dreams	37.35	25.53	22	9607	10494	63468899
Pain	35.67	25.53	36	9593	740592	62738801
Rash maculo-papular	35.24	25.53	33	9596	31863	63447530
Anaemia	35.19	25.53	111	9518	293319	63186074
Alanine aminotransferase increased	34.80	25.53	59	9570	103711	63375682
Twin pregnancy	34.55	25.53	11	9618	1162	63478231
Tongue discomfort	34.38	25.53	13	9616	2290	63477103
Congenital anomaly	33.84	25.53	12	9617	1764	63477629
Encephalocele	33.51	25.53	7	9622	135	63479258
Endometrial sarcoma	32.85	25.53	5	9624	12	63479381
Maternal drugs affecting foetus	32.84	25.53	16	9613	5226	63474167
Cardiac malposition	32.76	25.53	6	9623	56	63479337
Pregnancy on oral contraceptive	31.69	25.53	10	9619	1027	63478366
Pachygyria	31.18	25.53	4	9625	0	63479393
Aspartate aminotransferase increased	31.16	25.53	52	9577	90225	63389168
Neural tube defect	31.05	25.53	7	9622	195	63479198
Gene mutation	30.77	25.53	11	9618	1654	63477739
Hepatic displacement	29.69	25.53	5	9624	27	63479366
Retinal toxicity	29.66	25.53	10	9619	1265	63478128
Pre-eclampsia	29.56	25.53	18	9611	9115	63470278
Meningitis cryptococcal	28.90	25.53	10	9619	1367	63478026
Peptic ulcer	28.73	25.53	14	9615	4573	63474820
Diastasis recti abdominis	28.34	25.53	5	9624	37	63479356
Anencephaly	28.14	25.53	7	9622	300	63479093
Polymyalgia rheumatica	28.12	25.53	13	9616	3778	63475615
Jaundice	28.05	25.53	28	9601	29223	63450170
Isosporiasis	27.99	25.53	5	9624	40	63479353
HIV-associated neurocognitive disorder	27.97	25.53	6	9623	132	63479261
Polydactyly	27.83	25.53	7	9622	314	63479079
Lipoatrophy	27.79	25.53	7	9622	316	63479077
Meningomyelocele	27.67	25.53	8	9621	610	63478783
AIDS related complication	27.13	25.53	4	9625	7	63479386
Renal tubular acidosis	26.89	25.53	10	9619	1682	63477711
Hydrocephalus	26.82	25.53	14	9615	5286	63474107
Type III hyperlipidaemia	26.78	25.53	4	9625	8	63479385
Congenital hydrocephalus	26.49	25.53	6	9623	171	63479222
Cytomegalovirus chorioretinitis	26.33	25.53	10	9619	1783	63477610
Renal tubular disorder	25.68	25.53	11	9618	2671	63476722

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Depression	1393.23	16.72	798	19329	96300	34840504
Drug interaction	1025.54	16.72	920	19207	225026	34711778
Immune reconstitution inflammatory syndrome	896.18	16.72	291	19836	8468	34928336
Viral mutation identified	760.90	16.72	201	19926	2753	34934051
Virologic failure	737.51	16.72	203	19924	3277	34933527
Lipodystrophy acquired	616.86	16.72	175	19952	3169	34933635
Pathogen resistance	577.63	16.72	214	19913	9268	34927536
Psychiatric decompensation	363.83	16.72	113	20014	2824	34933980
Mitochondrial toxicity	314.07	16.72	99	20028	2600	34934204
Loss of personal independence in daily activities	301.46	16.72	205	19922	32974	34903830
Depression suicidal	300.30	16.72	94	20033	2411	34934393
Tearfulness	294.50	16.72	94	20033	2573	34934231
Drug resistance	263.96	16.72	172	19955	25755	34911049
Progressive external ophthalmoplegia	255.09	16.72	73	20054	1362	34935442
Depressive symptom	244.21	16.72	83	20044	2776	34934028
Eyelid ptosis	223.80	16.72	94	20033	5672	34931132
Psychomotor skills impaired	222.53	16.72	84	20043	3822	34932982
Paranoia	209.37	16.72	113	20014	11955	34924849
Lipoatrophy	151.93	16.72	39	20088	472	34936332
Foetal exposure during pregnancy	145.50	16.72	142	19985	37959	34898845
Psychotic disorder	140.86	16.72	115	20012	24337	34912467
Diplopia	120.37	16.72	90	20037	16753	34920051
CD4 lymphocytes decreased	119.67	16.72	43	20084	1698	34935106
Abnormal dreams	109.66	16.72	63	20064	7515	34929289
Suicidal ideation	102.06	16.72	121	20006	40267	34896537
Pulmonary tuberculosis	98.05	16.72	50	20077	4704	34932100
Treatment failure	95.76	16.72	126	20001	46571	34890233
Retinal toxicity	94.68	16.72	26	20101	414	34936390
Psychomotor retardation	91.97	16.72	44	20083	3606	34933198
Hyperlipidaemia	91.45	16.72	72	20055	14457	34922347
Multiple-drug resistance	85.13	16.72	47	20080	5192	34931612
Viral load increased	84.22	16.72	37	20090	2490	34934314
Trisomy 18	80.29	16.72	26	20101	745	34936059
Blood HIV RNA increased	79.39	16.72	29	20098	1201	34935603
Hydrops foetalis	77.29	16.72	26	20101	841	34935963
Off label use	76.05	16.72	78	20049	419446	34517358
Cleft lip and palate	76	16.72	26	20101	886	34935918
Kaposi's sarcoma	72.91	16.72	25	20102	858	34935946
Hyperlactacidaemia	71.89	16.72	35	20092	2981	34933823
Fanconi syndrome acquired	69.11	16.72	30	20097	1961	34934843
Ophthalmoplegia	68.06	16.72	29	20098	1811	34934993
Ultrasound antenatal screen	67.19	16.72	21	20106	535	34936269
Treatment noncompliance	65.75	16.72	81	20046	28019	34908785
Gynaecomastia	65.25	16.72	51	20076	10129	34926675
Renal tubular disorder	62.92	16.72	37	20090	4606	34932198
Hepatic fibrosis	57.97	16.72	35	20092	4572	34932232
Hypertriglyceridaemia	57.80	16.72	44	20083	8404	34928400
Fanconi syndrome	56.72	16.72	25	20102	1695	34935109
HIV-associated neurocognitive disorder	54.47	16.72	16	20111	328	34936476
Meningitis cryptococcal	51.66	16.72	26	20101	2378	34934426
Pneumonia	51.50	16.72	81	20046	362546	34574258
Dyslipidaemia	51.23	16.72	39	20088	7449	34929355
Febrile neutropenia	46.25	16.72	11	20116	136838	34799966
Immune reconstitution inflammatory syndrome associated tuberculosis	45.88	16.72	15	20112	443	34936361
Fatigue	45.22	16.72	91	20036	370562	34566242
Death	45.02	16.72	102	20025	397947	34538857
Prescribed overdose	44.99	16.72	42	20085	10605	34926199
Nervous system disorder	44.23	16.72	48	20079	14495	34922309
Osteoporosis	44.21	16.72	45	20082	12623	34924181
Portal hypertension	43.87	16.72	28	20099	4034	34932770
Abortion spontaneous	43.74	16.72	14	20113	386	34936418
Fall	43.56	16.72	32	20095	202853	34733951
Anxiety	43.52	16.72	141	19986	99287	34837517
Drug ineffective	43.27	16.72	128	19999	456623	34480181
Neuropsychiatric symptoms	42.83	16.72	17	20110	885	34935919
Drug abuse	42.50	16.72	4	20123	99092	34837712
Pain	41.76	16.72	34	20093	204641	34732163
Product dose omission issue	41.69	16.72	9	20118	119702	34817102
Hypotension	41.40	16.72	40	20087	221609	34715195
Life expectancy shortened	40.52	16.72	9	20118	55	34936749
Acquired immunodeficiency syndrome	40.19	16.72	14	20113	504	34936300
Nephropathy toxic	39.07	16.72	42	20085	12546	34924258
Retroviral rebound syndrome	38.62	16.72	7	20120	11	34936793
Lymph node tuberculosis	37.75	16.72	13	20114	452	34936352
Proteinuria	37.71	16.72	50	20077	18592	34918212
Hydrocele	37.45	16.72	20	20107	2067	34934737
Constipation	37.45	16.72	16	20111	136966	34799838
Atrial fibrillation	37.31	16.72	12	20115	122381	34814423
Hepatitis	36.40	16.72	56	20071	23848	34912956
Renal impairment	36.04	16.72	128	19999	94385	34842419
Tuberculoid leprosy	34.84	16.72	8	20119	58	34936746
Hepatitis C	34.45	16.72	35	20092	9795	34927009
Aspartate aminotransferase increased	34.16	16.72	101	20026	67682	34869122
Lymphadenopathy	33.01	16.72	59	20068	28404	34908400
Nightmare	32.87	16.72	41	20086	14350	34922454
Tuberculosis	32.76	16.72	32	20095	8545	34928259
Neurosyphilis	32.38	16.72	7	20120	37	34936767
Dyspnoea	31.84	16.72	111	20016	376671	34560133
Lactic acidosis	31.62	16.72	65	20062	34707	34902097
Mycobacterium avium complex infection	31.39	16.72	19	20108	2492	34934312
Megakaryocytes increased	30.95	16.72	7	20120	47	34936757
Developmental hip dysplasia	30.60	16.72	10	20117	295	34936509
Conductive deafness	30.44	16.72	10	20117	300	34936504
HIV infection	30.30	16.72	15	20112	1324	34935480
Blood triglycerides increased	30.22	16.72	39	20088	14120	34922684
Blood pressure increased	29.91	16.72	7	20120	88095	34848709
Genotype drug resistance test positive	29.44	16.72	14	20113	1131	34935673
Secondary syphilis	29.14	16.72	7	20120	63	34936741
COVID-19	28.74	16.72	5	20122	77545	34859259
Cachexia	27.80	16.72	27	20100	7159	34929645
Back pain	27.71	16.72	18	20109	121771	34815033
Mycobacterium avium complex immune restoration disease	27.55	16.72	6	20121	33	34936771
Infection	27.55	16.72	9	20118	90906	34845898
Cytomegalovirus chorioretinitis	27.47	16.72	20	20107	3569	34933235
Hepatosplenomegaly	26.96	16.72	21	20106	4148	34932656
Cryptococcosis	26.93	16.72	17	20110	2402	34934402
Congenital umbilical hernia	26.64	16.72	9	20118	295	34936509
Mitochondrial cytopathy	26.37	16.72	8	20119	184	34936620
Hepatomegaly	25.98	16.72	31	20096	10365	34926439
Product use issue	25.94	16.72	3	20124	63213	34873591
Intracranial pressure increased	25.74	16.72	20	20107	3935	34932869
Osteonecrosis	25.70	16.72	37	20090	14853	34921951
Blood lactic acid increased	25.50	16.72	25	20102	6703	34930101
Alanine aminotransferase increased	24.66	16.72	102	20025	80713	34856091
Hypophosphataemia	24.52	16.72	31	20096	10995	34925809
Night blindness	24.42	16.72	8	20119	238	34936566
Histoplasmosis disseminated	24.28	16.72	13	20114	1350	34935454
Sickle cell disease	24.28	16.72	7	20120	134	34936670
Hepatic cirrhosis	24.19	16.72	39	20088	17275	34919529
Hepatitis B	24.12	16.72	23	20104	5960	34930844
Liver transplant	23.78	16.72	16	20111	2518	34934286
Toxoplasma serology positive	23.61	16.72	4	20123	3	34936801
Renal tubular dysfunction	23.55	16.72	9	20118	423	34936381
Platelet count decreased	23.03	16.72	21	20106	119696	34817108
Hepatotoxicity	22.97	16.72	43	20084	21442	34915362
Urinary tract inflammation	22.75	16.72	7	20120	169	34936635
Meningitis tuberculous	22.73	16.72	10	20117	675	34936129
Oral candidiasis	22.24	16.72	31	20096	12079	34924725
Paradoxical drug reaction	21.93	16.72	17	20110	3334	34933470
Vanishing bile duct syndrome	21.84	16.72	11	20116	1007	34935797
Pneumocystis jirovecii pneumonia	21.76	16.72	40	20087	19670	34917134
Drug-induced liver injury	21.76	16.72	50	20077	28782	34908022
Mitochondrial myopathy	21.70	16.72	7	20120	198	34936606
Lipids increased	21.42	16.72	11	20116	1049	34935755
Synostosis	21.37	16.72	6	20121	104	34936700
Polyneuropathy chronic	21.23	16.72	5	20122	41	34936763
Caesarean section	21.12	16.72	14	20113	2150	34934654
Nasopharyngitis	21.06	16.72	7	20120	69961	34866843
Limb deformity	20.80	16.72	9	20118	583	34936221
Renal tubular acidosis	20.24	16.72	14	20113	2305	34934499
Talipes	20.13	16.72	13	20114	1910	34934894
Glycosuria	19.83	16.72	11	20116	1226	34935578
Lipohypertrophy	19.61	16.72	7	20120	271	34936533
Disease progression	19.57	16.72	20	20107	108057	34828747
Anal cancer	19.48	16.72	8	20119	455	34936349
Progressive multifocal leukoencephalopathy	19.45	16.72	26	20101	9738	34927066
Nodular regenerative hyperplasia	19.38	16.72	10	20117	963	34935841
Korsakoff's syndrome	19.38	16.72	3	20124	0	34936804
Gamma-glutamyltransferase increased	19.16	16.72	48	20079	29183	34907621
Birth mark	18.79	16.72	6	20121	164	34936640
Elbow synostosis	18.69	16.72	4	20123	20	34936784
Amylase increased	18.67	16.72	20	20107	5948	34930856
Subacute sclerosing panencephalitis	18.52	16.72	4	20123	21	34936783
Hypercholesterolaemia	18.49	16.72	24	20103	8738	34928066
Neck deformity	18.42	16.72	5	20122	76	34936728
Osteoporotic fracture	18.27	16.72	10	20117	1085	34935719
Exposure during pregnancy	18.12	16.72	24	20103	8910	34927894
Congenital tuberculosis	18.07	16.72	4	20123	24	34936780
Pulmonary oedema	17.75	16.72	3	20124	47526	34889278
Castleman's disease	17.67	16.72	4	20123	27	34936777
Meningomyelocele	17.61	16.72	6	20121	202	34936602
Eyelid ptosis congenital	17.53	16.72	5	20122	92	34936712
Congenital bowing of long bones	17.42	16.72	4	20123	29	34936775
Congenital eyelid malformation	17.23	16.72	5	20122	98	34936706
Pain in extremity	17.18	16.72	29	20098	126484	34810320
Therapeutic product effect incomplete	17.18	16.72	4	20123	50537	34886267
Osteomalacia	17.05	16.72	9	20118	908	34935896
Nephrolithiasis	17.02	16.72	47	20080	30286	34906518
Meconium ileus	16.75	16.72	4	20123	35	34936769

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome	1350.09	16.73	379	22844	13462	79707703
Depression	859.34	16.73	617	22606	216173	79504992
Viral mutation identified	796.99	16.73	192	23031	3666	79717499
Drug interaction	776.27	16.73	765	22458	414418	79306747
Virologic failure	745.85	16.73	185	23038	4006	79717159
Lipodystrophy acquired	745.07	16.73	186	23037	4139	79717026
Drug resistance	571.67	16.73	268	22955	41945	79679220
Pathogen resistance	457.42	16.73	168	23055	14174	79706991
Abortion spontaneous	448.35	16.73	203	23020	29304	79691861
Psychiatric decompensation	401.84	16.73	112	23111	3851	79717314
Mitochondrial toxicity	380.85	16.73	102	23121	3012	79718153
Abortion induced	329.33	16.73	110	23113	6999	79714166
Depression suicidal	328.26	16.73	95	23128	3747	79717418
Progressive external ophthalmoplegia	303.93	16.73	73	23150	1372	79719793
Tearfulness	301.89	16.73	99	23124	5946	79715219
Psychomotor skills impaired	250.40	16.73	83	23140	5154	79716011
Stillbirth	247.87	16.73	77	23146	3878	79717287
Depressive symptom	230.01	16.73	82	23141	6341	79714824
Paranoia	225.27	16.73	111	23112	19321	79701844
Loss of personal independence in daily activities	222.31	16.73	206	23017	102374	79618791
Maternal exposure during pregnancy	219.54	16.73	233	22990	136305	79584860
Blood HIV RNA increased	215.31	16.73	58	23165	1750	79719415
Eyelid ptosis	213.22	16.73	90	23133	10954	79710211
Exposure during pregnancy	201.75	16.73	194	23029	100938	79620227
Pregnancy	194.18	16.73	112	23111	26739	79694426
Pulmonary tuberculosis	192.56	16.73	76	23147	7789	79713376
Psychotic disorder	165.75	16.73	119	23104	41283	79679882
CD4 lymphocytes decreased	163.87	16.73	51	23172	2583	79718582
Lipoatrophy	156.26	16.73	37	23186	652	79720513
Caesarean section	137.55	16.73	69	23154	12466	79708699
Fanconi syndrome acquired	129.99	16.73	43	23180	2651	79718514
Retinal toxicity	129.95	16.73	37	23186	1374	79719791
Viral load increased	126.19	16.73	43	23180	2905	79718260
Diplopia	117.73	16.73	89	23134	33377	79687788
Hydrops foetalis	116.82	16.73	30	23193	748	79720417
Treatment noncompliance	105.51	16.73	101	23122	52167	79668998
Ultrasound antenatal screen	105.42	16.73	27	23196	666	79720499
Suicidal ideation	104.76	16.73	120	23103	76220	79644945
Pain	101.85	16.73	39	23184	703763	79017402
Multiple-drug resistance	101.12	16.73	50	23173	8758	79712407
Cleft lip and palate	100.35	16.73	26	23197	672	79720493
Lactic acidosis	98.91	16.73	112	23111	70247	79650918
Meningitis cryptococcal	96.88	16.73	37	23186	3469	79717696
Immune reconstitution inflammatory syndrome associated tuberculosis	95.70	16.73	26	23197	810	79720355
Trisomy 18	93.97	16.73	24	23199	585	79720580
Portal hypertension	92.60	16.73	44	23179	7064	79714101
Nephropathy toxic	91.72	16.73	63	23160	20356	79700809
Psychomotor retardation	88.97	16.73	41	23182	6143	79715022
Gynaecomastia	83.44	16.73	42	23181	7639	79713526
Normal newborn	80.75	16.73	40	23183	7032	79714133
Tuberculosis	75.70	16.73	50	23173	15148	79706017
Abnormal dreams	75.62	16.73	45	23178	11367	79709798
Fanconi syndrome	74.84	16.73	29	23194	2827	79718338
Pregnancy on contraceptive	70.98	16.73	21	23202	894	79720271
Hepatic fibrosis	70.95	16.73	37	23186	7243	79713922
Ophthalmoplegia	70.78	16.73	28	23195	2884	79718281
HIV-associated neurocognitive disorder	70.00	16.73	17	23206	335	79720830
Renal tubular disorder	69.09	16.73	35	23188	6451	79714714
Hyperlipidaemia	67.54	16.73	58	23165	26035	79695130
Aspartate aminotransferase increased	67.32	16.73	134	23089	138507	79582658
Hepatomegaly	63.74	16.73	49	23174	18825	79702340
Joint swelling	62.35	16.73	6	23217	288640	79432525
Fatigue	62.24	16.73	110	23113	929617	78791548
Hyperlactacidaemia	61.97	16.73	31	23192	5564	79715601
Lymph node tuberculosis	60.42	16.73	19	23204	995	79720170
Hypertriglyceridaemia	58.85	16.73	40	23183	12700	79708465
Drug ineffective	56.46	16.73	147	23076	1080766	78640399
Alanine aminotransferase increased	56.09	16.73	137	23086	162433	79558732
Nasopharyngitis	55.57	16.73	5	23218	253876	79467289
Dyslipidaemia	54.87	16.73	37	23186	11596	79709569
Hepatic cytolysis	53.89	16.73	52	23171	27099	79694066
Pregnancy with implant contraceptive	52.77	16.73	20	23203	1836	79719329
Mycobacterium avium complex infection	52.46	16.73	26	23197	4574	79716591
Nightmare	52.22	16.73	50	23173	25811	79695354
Live birth	51.24	16.73	43	23180	18701	79702464
Cytomegalovirus chorioretinitis	50.93	16.73	27	23196	5463	79715702
Lymphadenopathy	49.58	16.73	69	23154	53178	79667987
Rheumatoid arthritis	48.76	16.73	3	23220	208467	79512698
Kaposi's sarcoma	48.49	16.73	15	23208	744	79720421
Fall	47.85	16.73	43	23180	487586	79233579
Off label use	47.60	16.73	123	23100	907092	78814073
Megakaryocytes increased	46.77	16.73	10	23213	108	79721057
Product dose omission issue	46.59	16.73	8	23215	247529	79473636
Cachexia	44.65	16.73	32	23191	11051	79710114
Arthralgia	44.50	16.73	61	23162	571742	79149423
Foetal exposure during pregnancy	44.11	16.73	25	23198	5765	79715400
Infection	42.96	16.73	9	23214	241703	79479462
Osteomalacia	42.26	16.73	16	23207	1464	79719701
Cholestatic liver injury	42.20	16.73	23	23200	4918	79716247
Meningitis tuberculous	41.68	16.73	15	23208	1190	79719975
Tuberculoid leprosy	41.62	16.73	9	23214	103	79721062
Nervous system disorder	41.59	16.73	45	23178	26811	79694354
Hepatitis	41.47	16.73	65	23158	55662	79665503
Genotype drug resistance test positive	40.48	16.73	15	23208	1293	79719872
Sinusitis	39.83	16.73	5	23218	195496	79525669
Ectopic pregnancy	39.72	16.73	16	23207	1727	79719438
Aplasia pure red cell	39.63	16.73	26	23197	7784	79713381
Blood triglycerides increased	39.33	16.73	39	23184	21001	79700164
Swelling	38.65	16.73	8	23215	216703	79504462
Dyspnoea	38.49	16.73	125	23098	856900	78864265
Renal impairment	38.41	16.73	117	23106	157666	79563499
Hepatic cirrhosis	38.27	16.73	49	23174	34857	79686308
Acquired immunodeficiency syndrome	37.26	16.73	10	23213	297	79720868
Anaemia	37.13	16.73	239	22984	444776	79276389
Constipation	37.13	16.73	18	23205	283032	79438133
Pain in extremity	37.12	16.73	31	23192	364507	79356658
Therapeutic product effect decreased	36.46	16.73	3	23220	163860	79557305
Proteinuria	36.22	16.73	46	23177	32456	79688709
Pneumocystis jirovecii pneumonia	36.21	16.73	46	23177	32462	79688703
Abdominal discomfort	35.97	16.73	14	23209	250713	79470452
Renal tubular dysfunction	35.88	16.73	12	23211	765	79720400
Premature delivery	35.78	16.73	39	23184	23428	79697737
Neuropsychiatric symptoms	35.78	16.73	14	23209	1401	79719764
Pneumonia	35.73	16.73	88	23135	660158	79061007
Night blindness	35.43	16.73	11	23212	552	79720613
Tuberculoma of central nervous system	34.98	16.73	11	23212	576	79720589
Low density lipoprotein increased	34.98	16.73	25	23198	8597	79712568
Arthropathy	34.96	16.73	5	23218	177106	79544059
Cryptococcosis	34.74	16.73	18	23205	3475	79717690
Back pain	34.66	16.73	23	23200	304157	79417008
Febrile neutropenia	34.65	16.73	12	23211	230987	79490178
Drug-induced liver injury	34.61	16.73	66	23157	66051	79655114
Autoimmune hepatitis	34.22	16.73	28	23195	11755	79709410
Malaria	34.12	16.73	10	23213	412	79720753
Hepatitis C	33.93	16.73	28	23195	11897	79709268
Secondary syphilis	33.60	16.73	7	23216	66	79721099
Prescribed overdose	32.18	16.73	47	23176	37836	79683329
Hypophosphataemia	31.95	16.73	34	23189	19879	79701286
Endometrial sarcoma	31.77	16.73	5	23218	6	79721159
Disseminated tuberculosis	31.70	16.73	18	23205	4165	79717000
Jaundice	31.37	16.73	56	23167	53293	79667872
Renal tubular acidosis	31.35	16.73	17	23206	3597	79717568
Hepatitis B	31.16	16.73	23	23200	8309	79712856
Hepatosplenomegaly	30.30	16.73	20	23203	6049	79715116
Extrapulmonary tuberculosis	30.13	16.73	9	23214	396	79720769
Mitochondrial cytopathy	30.02	16.73	9	23214	401	79720764
Retroviral rebound syndrome	29.59	16.73	5	23218	12	79721153
Intracranial pressure increased	28.96	16.73	22	23201	8300	79712865
Atrial fibrillation	28.46	16.73	11	23212	197875	79523290
Blood pressure increased	28.39	16.73	13	23210	211347	79509818
Musculoskeletal stiffness	28.19	16.73	8	23215	175000	79546165
HIV infection	27.96	16.73	11	23212	1116	79720049
Therapeutic product effect incomplete	27.95	16.73	4	23219	141641	79579524
Gamma-glutamyltransferase increased	27.90	16.73	54	23169	54626	79666539
Hypercholesterolaemia	27.84	16.73	34	23189	23061	79698104
Hepatotoxicity	27.79	16.73	52	23171	51300	79669865
Mycobacterium avium complex immune restoration disease	27.47	16.73	5	23218	21	79721144
Pregnancy on oral contraceptive	27.30	16.73	10	23213	835	79720330
Injection site pain	27.24	16.73	3	23220	129835	79591330
Pancreatitis	27.12	16.73	61	23162	68514	79652651
Meningomyelocele	27.10	16.73	5	23218	23	79721142
Hepatitis fulminant	27.06	16.73	20	23203	7242	79713923
Neurosyphilis	26.44	16.73	5	23218	27	79721138
Anxiety	26.19	16.73	142	23081	248370	79472795
Nodular regenerative hyperplasia	25.96	16.73	11	23212	1350	79719815
Hypotension	25.95	16.73	56	23167	440261	79280904
Osteoporosis	25.87	16.73	52	23171	54060	79667105
Inappropriate schedule of product administration	25.84	16.73	4	23219	133624	79587541
COVID-19	25.78	16.73	7	23216	157667	79563498
Liver transplant	25.60	16.73	16	23207	4407	79716758
Oral candidiasis	25.51	16.73	37	23186	29591	79691574
Conductive deafness	25.18	16.73	7	23216	238	79720927
Hepatic necrosis	25.13	16.73	21	23202	9079	79712086
Rash scarlatiniform	25.12	16.73	7	23216	240	79720925
Oesophageal candidiasis	24.89	16.73	21	23202	9197	79711968
Influenza	24.79	16.73	4	23219	129602	79591563
Red blood cell abnormality	24.55	16.73	9	23214	753	79720412
Gene mutation	24.32	16.73	13	23210	2673	79718492
Weight increased	24.25	16.73	27	23196	277359	79443806
Type III hyperlipidaemia	24.18	16.73	4	23219	8	79721157
Transaminases increased	23.88	16.73	49	23174	51694	79669471
Mitochondrial myopathy	23.84	16.73	7	23216	290	79720875
Central nervous system immune reconstitution inflammatory response	23.47	16.73	5	23218	53	79721112
Rash maculo-papular	23.43	16.73	51	23172	56027	79665138
AIDS related complication	23.14	16.73	5	23218	57	79721108
Vanishing bile duct syndrome	23.14	16.73	11	23212	1767	79719398
Cerebral toxoplasmosis	23	16.73	12	23211	2350	79718815
Bronchitis	22.92	16.73	5	23218	130639	79590526
Paradoxical drug reaction	22.84	16.73	18	23205	7167	79713998
Product use issue	22.40	16.73	17	23206	209805	79511360
CD4 lymphocytes	22.13	16.73	4	23219	16	79721149
Premature rupture of membranes	21.76	16.73	14	23209	4055	79717110
Nephrolithiasis	21.74	16.73	48	23175	53243	79667922
Drug intolerance	21.70	16.73	27	23196	264092	79457073
Folate deficiency	21.61	16.73	13	23210	3347	79717818
Haemophagocytic lymphohistiocytosis	21.37	16.73	29	23194	21808	79699357
Progressive multifocal leukoencephalopathy	21.15	16.73	28	23195	20572	79700593
Arthritis	20.98	16.73	4	23219	114876	79606289
Glycosuria	20.97	16.73	11	23212	2177	79718988
Gait disturbance	20.67	16.73	18	23205	207488	79513677
Viral load decreased	20.65	16.73	4	23219	25	79721140
Abdominal pain upper	20.44	16.73	21	23202	223798	79497367
Pericarditis	20.43	16.73	3	23220	104233	79616932
Stevens-Johnson syndrome	20.37	16.73	39	23184	39127	79682038
Completed suicide	20.32	16.73	25	23198	245742	79475423
Urinary tract inflammation	20.31	16.73	6	23217	254	79720911
Cerebellar syndrome	20.21	16.73	15	23208	5465	79715700
Hyperphosphaturia	20.06	16.73	5	23218	110	79721055
Discomfort	19.76	16.73	6	23217	125611	79595554
Alopecia	19.70	16.73	23	23200	231332	79489833
Granulomatous liver disease	19.68	16.73	9	23214	1324	79719841
Twin pregnancy	19.65	16.73	8	23215	888	79720277
Intentional product use issue	19.59	16.73	92	23131	152020	79569145
Amylase increased	19.52	16.73	20	23203	11189	79709976
Subacute sclerosing panencephalitis	19.27	16.73	4	23219	37	79721128
Visual field defect	19.23	16.73	18	23205	9027	79712138
Hepatic encephalopathy	19.11	16.73	29	23194	24137	79697028
Hepatic steatosis	18.92	16.73	37	23186	37701	79683464
Lipids abnormal	18.77	16.73	7	23216	614	79720551
CSF HIV escape syndrome	18.61	16.73	6	23217	341	79720824
Toxoplasma serology positive	18.56	16.73	4	23219	45	79721120
Blood alkaline phosphatase increased	18.17	16.73	50	23173	63614	79657551
Acquired gene mutation	17.98	16.73	10	23213	2223	79718942
Opportunistic infection	17.91	16.73	11	23212	2939	79718226
Anaemia macrocytic	17.74	16.73	14	23209	5583	79715582
Nausea	17.69	16.73	186	23037	957010	78764155
Isosporiasis	17.63	16.73	5	23218	183	79720982
Oropharyngeal pain	17.60	16.73	5	23218	109348	79611817
Hepatic function abnormal	17.57	16.73	54	23169	73053	79648112
Hypertrophic cardiomyopathy	17.54	16.73	10	23213	2330	79718835
Histoplasmosis disseminated	17.49	16.73	10	23213	2343	79718822
Osteonecrosis	17.46	16.73	32	23191	31063	79690102
Blood lactic acid increased	17.40	16.73	20	23203	12724	79708441
Condition aggravated	17.34	16.73	81	23142	501043	79220122
Oropharyngeal candidiasis	17.32	16.73	9	23214	1748	79719417
Spinocerebellar disorder	17.27	16.73	3	23220	9	79721156
Acute stress disorder	17.15	16.73	6	23217	438	79720727
Antiviral drug level above therapeutic	16.97	16.73	4	23219	69	79721096
Stomatitis	16.83	16.73	11	23212	146746	79574419

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AG03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors
ATC	J05AR06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
ATC	J05AR11	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations
FDA MoA	N0000009948	Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT	N0000175460	Non-Nucleoside Analog
FDA EPC	N0000175463	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D065695	Cytochrome P-450 CYP2B6 Inducers
MeSH PA	D065689	Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA	D065688	Cytochrome P-450 CYP2C9 Inhibitors
MeSH PA	D065701	Cytochrome P-450 CYP3A Inducers
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D019384	Nucleic Acid Synthesis Inhibitors
MeSH PA	D018894	Reverse Transcriptase Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors
FDA MoA	N0000187064	Cytochrome P450 2B6 Inducers
FDA MoA	N0000190118	Cytochrome P450 3A Inducers
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:53756	reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Prevention of HIV Infection after Exposure	off-label use
Osteomalacia	contraindication	4598005	DOID:10573
Hypophosphatemia	contraindication	4996001
Suicidal thoughts	contraindication	6471006
Hypercholesterolemia	contraindication	13644009
Depressive disorder	contraindication	35489007
Fanconi syndrome	contraindication	40488004	DOID:1062
Hypokalemia	contraindication	43339004
Cardiovascular disease	contraindication	49601007	DOID:1287
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Aggressive behavior	contraindication	61372001
Chronic type B viral hepatitis	contraindication	61977001
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Prolonged QT interval	contraindication	111975006
Chronic hepatitis C	contraindication	128302006
Seizure disorder	contraindication	128613002
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Paranoid disorder	contraindication	191667009
Steatosis of liver	contraindication	197321007
Mania	contraindication	231494001
Disease of liver	contraindication	235856003	DOID:409
Pathological fracture	contraindication	268029009
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Osteopenia	contraindication	312894000
Breastfeeding (mother)	contraindication	413712001
Obesity	contraindication	414916001	DOID:9970
Family history of sudden death	contraindication	430283008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.6	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8592397	Jan. 13, 2024	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8592397	Jan. 13, 2024	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	8716264	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9457036	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9744181	Jan. 13, 2024	TREATMENT OF HIV INFECTION
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9018192	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9018192	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9545414	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG	ATRIPLA	GILEAD SCIENCES	N021937	July 12, 2006	RX	TABLET	ORAL	9545414	June 13, 2026	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN					WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.69		CHEMBL
Cholesterol 24-hydroxylase	Enzyme	Q9Y6A2	CP46A_HUMAN		Kd	6.10		CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN	INHIBITOR	IC50	4.76		IUPHAR
Reverse transcriptase/RNaseH	Enzyme		Q72547_9HIV1	INHIBITOR	Ki	8.52		CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1A2	INHIBITOR	IC50	8.30		WOMBAT-PK
Reverse transcriptase	Enzyme		Q9WKE8_9HIV1		IC50	8.89		CHEMBL
Reverse transcriptase protein	Unclassified		Q9WJQ2_9HIV1		Ki	8.07		CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	Unclassified		Q6QLK5_9HIV1		IC50	8.46		CHEMBL

External reference:

ID	Source
4021133	VUID
N0000148587	NUI
D00896	KEGG_DRUG
4021133	VANDF
C0674428	UMLSCUI
CHEBI:119486	CHEBI
EFZ	PDB_CHEM_ID
CHEMBL223228	ChEMBL_ID
DB00625	DRUGBANK_ID
C098320	MESH_SUPPLEMENTAL_RECORD_UI
64139	PUBCHEM_CID
11287	IUPHAR_LIGAND_ID
7718	INN_ID
JE6H2O27P8	UNII
195084	RXNORM
11884	MMSL
210786	MMSL
7492	MMSL
d04355	MMSL
007651	NDDF
116078005	SNOMEDCT_US
387001004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0470	CAPSULE, GELATIN COATED	50 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0470	CAPSULE, GELATIN COATED	50 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0470	CAPSULE, GELATIN COATED	50 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0474	CAPSULE, GELATIN COATED	200 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0474	CAPSULE, GELATIN COATED	200 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0474	CAPSULE, GELATIN COATED	200 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0510	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0510	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	0056-0510	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5234	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	HUMAN PRESCRIPTION DRUG LABEL	3	0093-5234	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	0378-2233	TABLET, FILM COATED	600 mg	ORAL	ANDA	26 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	15584-0101	TABLET, FILM COATED	600 mg	ORAL	NDA	34 sections
Efavirenz	Human Prescription Drug Label	1	31722-504	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz	Human Prescription Drug Label	1	31722-504	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	HUMAN PRESCRIPTION DRUG LABEL	3	31722-736	TABLET, FILM COATED	600 mg	ORAL	ANDA	28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	33342-138	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, emtricitabine and tenofovir disoproxil fumarate	Human Prescription Drug Label	3	42385-915	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	42385-928	TABLET, FILM COATED	600 mg	ORAL	ANDA	30 sections
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate	Human Prescription Drug Label	3	42385-929	TABLET, FILM COATED	400 mg	ORAL	ANDA	30 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	42543-889	TABLET	600 mg	ORAL	ANDA	26 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	42543-889	TABLET	600 mg	ORAL	ANDA	26 sections
SYMFI LO	HUMAN PRESCRIPTION DRUG LABEL	3	49502-425	TABLET, FILM COATED	400 mg	ORAL	NDA	32 sections
SYMFI	HUMAN PRESCRIPTION DRUG LABEL	3	49502-475	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	51407-382	TABLET	600 mg	ORAL	ANDA	26 sections
Efavirenz	HUMAN PRESCRIPTION DRUG LABEL	1	51407-382	TABLET	600 mg	ORAL	ANDA	26 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	53808-0208	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
SUSTIVA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4668	TABLET, FILM COATED	600 mg	ORAL	NDA	29 sections
Atripla	HUMAN PRESCRIPTION DRUG LABEL	3	54868-5643	TABLET, FILM COATED	600 mg	ORAL	NDA	31 sections
Atripla Access	HUMAN PRESCRIPTION DRUG LABEL	3	61958-1601	TABLET, FILM COATED	600 mg	ORAL	EXPORT ONLY	34 sections